Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Blood (2025) 146 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2025-5643

Published: 2025

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Blood (2025) 146 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2025-3858

Published: 2025

Journal Articles

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas

Blood (2025) 146 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2025-3855

Published: 2025

Journal Articles

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

Blood (2025) 146 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2025-3169

Published: 2025

Journal Articles

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Maha Kamel, Monika Kutyna, Nirmal Robinson, David Ross, David Yeung, Agnes Yong, Anna Brown, Timothy Hughes, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2025-2065

Published: 2025

Journal Articles

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas, Daniel Tenen, Mahmoud Bassal

Blood (2025) 146 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2025-3231

Published: 2025

Journal Articles

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy

Kelly Lim, Monika Kutyna, Akash Kalro, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 1714.

https://doi.org/10.1182/blood-2025-1714

Published: 2025

Journal Articles

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Blood (2025) 146 (Supplement 1): 2087.

https://doi.org/10.1182/blood-2025-2087

Published: 2025

Journal Articles

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Lynette Chee, Shuhying Tan, David Valcarcel, Anish Puliyayil, Alejandro Arbelaez, Montserrat Arnan, David Ross, Devendra Hiwase, Teresa Bernal, Thomas Cluzeau, Aristoteles Giagounidis, Jen Salstrom, Radha Ramesh, Camden Bay, Kevin Galinsky, Leopold Sellner, Kaveri Suryanarayan, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 787.

https://doi.org/10.1182/blood-2025-787

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Blood (2025) 146 (Supplement 1): 3798.

https://doi.org/10.1182/blood-2025-3798

Published: 2025

Journal Articles

Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant

Smita Hiwase, Alia Cibich, Leanne Purins, David Yeung, Devendra Hiwase, Peter Bardy

Blood (2025) 146 (Supplement 1): 2508.

https://doi.org/10.1182/blood-2025-2508

Published: 2025

Journal Articles

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Rithin Nedumannil, Michael Ashby, James Rowland, Jacques A. J. Malherbe, Jared Fairbank, Kelli Gray, Sun Loo, Matthew Wright, John Reynolds, Devendra Hiwase, Paula Marlton, Shaun Fleming, Ashish Bajel, Andrew H. Wei

Blood (2025) 146 (13): 1625–1629.

https://doi.org/10.1182/blood.2025028594

Published: 2025

Includes: Supplemental data

Journal Articles

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

Devendra Hiwase, Zoe Price, Chung How Kok, Monika Kutyna, Deepak Singhal, Naranie Shanmuganathan, Lesley Rawlings, David M Ross, David T Yeung, Anna Brown, Christopher N. Hahn, Lucy Godley, Caner Saygin, Hamish S Scott

Blood (2024) 144 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2024-211795

Published: 2024

Journal Articles

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Kevin Hung, Aref Al-Kali, Carla Toop, Mrinal M. Patnaik, Zoe Price, Taxiarchis Kourelis, Daniel Thomas, Morie A. Gertz, Hossein Anani, Wilson I. Gonsalves, Chung Hoow Kok, Ayalew Tefferi, Devendra Hiwase, Mithun V Shah

Blood (2024) 144 (Supplement 1): 4594.

https://doi.org/10.1182/blood-2024-211931

Published: 2024

Journal Articles

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Thomas Wiseman, Michaela Spooner, Shreyas Khanna, Kevin Hung, Carla Toop, Deepak Singhal, David M Ross, David T Yeung, Anna Brown, Hamish S Scott, Christopher N. Hahn, Daniel Thomas, Chung How Kok, Devendra Hiwase

Blood (2024) 144 (Supplement 1): 3208.

https://doi.org/10.1182/blood-2024-209123

Published: 2024

Journal Articles

Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Julie A.I. Thoms, Feng Yan, Henry R. Hampton, Sarah Davidson, Swapna Joshi, Jesslyn Saw, Chowdhury H. Sarowar, Xin Ying Lim, Andrea C Nunez, Purvi M. Kakadia, Golam Sarower Bhuyan, Xiaoheng Zou, Mary Nguyen, Elaheh S Ghodousi, Forrest C Koch, Fatemeh Vafaee, I. Richard Thompson, Mohammad M. Karimi, Russell Pickford, Mark J Raftery, Sally Hough, Griselda Buckland, Michelle Bailey, Yuvaraj Ghodke, Noorul Absar, Lachlin Vaughan, Leonardo Pasalic, Chun Yew Fong, Melita Kenealy, Devendra Hiwase, Rohanna Stoddart, Soma Mohammed, Linda Lee, Freda H Passam, Stephen Robert Larsen, Kevin J Spring, Kristen K Skarratt, Patricia Rebeiro, Peter Presgrave, William S Stevenson, Silvia Ling, Campbell Tiley, Stephen Fuller, Fernando Roncolato, Anoop K Enjeti, Dirk Hoenemann, Charlotte Lemech, Christopher J Jolly, Stefan K. Bohlander, David J. Curtis, Jason Wong, Ashwin Unnikrishnan, Mark S. Hertzberg, Jake Olivier, Mark N Polizzotto, John E Pimanda

Blood (2024) 144 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2024-201216

Published: 2024

Journal Articles

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Anoop K Enjeti, Suthanthirakannan Ramamoorthy, Devendra Hiwase, Asma Ashraf, Belinda E Butcher, Sushma Kollipara, Carolyn S. Grove, Andrew H Wei, Jake Shortt

Blood (2024) 144 (Supplement 1): 4605.1.

https://doi.org/10.1182/blood-2024-202604

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Reduced overall survival in TP53-mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy

Integrated prognostic model for TP53‑mutated myeloid neoplasms across all myeloid neoplasm subtypes

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Clinical NGS detection of TP53 mutations in chronic phase primary myelofibrosis: Comparative analyses of genotype and prognosis

Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant

Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML

Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure

TP53 -Mutated Therapy-Related Myeloid Neoplasms Are Associated with a Long Latency and Are More Prevalent in Patients with Primary Hematological Cancers Compared to Solid Tumors

Dynamic Assessment of RBC-Transfusion Dependency (RBC-TD) Improves the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification of MDS

Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells In Vivo

Targeting the Myelodysplasia (MDS) Inflammasome with the Oral Wnt/β-Catenin Pathway Inhibitor, ES-3000 in Combination with Oral Decitabine/Cedazuridine (ASTX727) an Australasian Leukaemia and Lymphoma Group Trial (ALLG MDS05/D1)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only